/Alex Natskovich

About Alex Natskovich

This author has not yet filled in any details.
So far Alex Natskovich has created 91 blog entries.

ISPOR 22ⁿᵈ Annual International Meeting

May 20-24, 2017 Boston, MA Booth#909 Precision will have a very strong presence again at ISPOR-- this year in Boston, MA. Come see us on the convention floor at Booth #909, and look for our expertise on display in numerous Precision-led short courses, forums, posters, issues panels, workshops and plenary sessions.

By | 2017-06-07T16:48:37+00:00 May 24th, 2017|EVENTS|0 Comments

Pricing and Contracting Strategy for a Biosimilar Launch

A large manufacturer client was preparing to launch a biosimilar into a highly competitive and complex market. In this case study, the brand team sought to learn how payers would view the product in relation to key competitors, understand decision drivers and thresholds, and identify potential competitive reactions resulting from any actions taken.

By | 2017-03-22T08:44:32+00:00 March 1st, 2017|Case Studies|0 Comments

Integrating Existing Data to Capture a Complete Picture of Payer Behavior

Learn how one pharmaceutical manufacturer overcame inconsistencies in tracking payer coverage and performance across the organization. With the application of a Payer Plan Hierarchy, the client was able to better understand the payer landscape and had a more direct and consistent line of sight on supporting product performance in managed markets contexts.

By | 2017-03-22T09:48:48+00:00 February 21st, 2017|Case Studies|0 Comments

Jeremy Schafer Addresses Sanofi/Regeneron’s dupilumab in BioPharm Insight

Precision for Value’s Jeremy Schafer comments on pricing and reimbursement of dupilumab, Sanofi/Regeneron’s first atopic dermatitis biologic, in BioPharm Insight.

By | 2017-03-16T14:54:32+00:00 February 17th, 2017|News|0 Comments

Precision for Value’s Hepatitis C Survey Discussed in Managed Healthcare Executive: Here’s What’s Missing

Precision for Value’s Jeremy Schafer highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.

By | 2017-03-20T08:34:03+00:00 February 17th, 2017|News|0 Comments